ArticleInfectious diseases now2021
Jaundice in a patient treated with Anakinra in a context of Covid-19.
H Tarhini, M Husain, N Poey, S Lariven, F-X Lescure, Y Yazdanpanah, A Gervais
Abstract readCase ReportsLetter
In one paragraphArticle in Infectious diseases now, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 3 institutions in 1 country.
H TarhiniDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France. Electronic address: hassantarhini01@gmail.com.
M HusainDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.
N PoeyDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.
S LarivenDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.
F-X LescureDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modeling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Y YazdanpanahDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modeling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
A GervaisDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.
Hôpital Bichat-Claude-Bernard · FRAssistance Publique – Hôpitaux de Paris · FRUniversité Claude Bernard Lyon 1 · FR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19 Drug TreatmentSARS-CoV-2Aged, 80 and overFemaleHumansHyperbilirubinemiaInterleukin 1 Receptor Antagonist ProteinJaundiceInterleukin 1 Receptor Antagonist Protein
Identifiers
PMID33010355
PMCPMC7526624
OpenAlexW3090933592
What OpenQuestion holds
Textmetadata
Read underepoch 390